TCRT PE Ratio & Valuation, Is TCRT Overvalued

Historical Valuation

Alaunos Therapeutics Inc (TCRT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.15. The fair price of Alaunos Therapeutics Inc (TCRT) is between NaN to NaN according to relative valuation method.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.98

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Alaunos Therapeutics Inc (TCRT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Alaunos Therapeutics Inc (TCRT) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 3.12, the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 4.21, the current P/B ratio is about -100.00% higher. Alaunos Therapeutics Inc (TCRT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -136.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -81.49%, the current FCF yield is about -100.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TCRT competitors is 1.18, providing a benchmark for relative valuation. Alaunos Therapeutics Inc Corp (TCRT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TCRT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TCRT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TCRT currently overvalued or undervalued?

What is Alaunos Therapeutics Inc (TCRT) fair value?

TCRT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Alaunos Therapeutics Inc (TCRT) is between NaN to NaN according to relative valuation method.

How does TCRT's valuation metrics compare to the industry average?

The average P/S ratio for TCRT's competitors is 1.18, providing a benchmark for relative valuation. Alaunos Therapeutics Inc Corp (TCRT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Alaunos Therapeutics Inc (TCRT) as of Mar 30 2026?

As of Mar 30 2026, Alaunos Therapeutics Inc (TCRT) has a P/B ratio of 0.00. This indicates that the market values TCRT at 0.00 times its book value.

What is the current FCF Yield for Alaunos Therapeutics Inc (TCRT) as of Mar 30 2026?

As of Mar 30 2026, Alaunos Therapeutics Inc (TCRT) has a FCF Yield of 0.00%. This means that for every dollar of Alaunos Therapeutics Inc's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Alaunos Therapeutics Inc (TCRT) as of Mar 30 2026?

As of Mar 30 2026, Alaunos Therapeutics Inc (TCRT) has a Forward P/E ratio of -0.08. This means the market is willing to pay $-0.08 for every dollar of Alaunos Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Alaunos Therapeutics Inc (TCRT) as of Mar 30 2026?

As of Mar 30 2026, Alaunos Therapeutics Inc (TCRT) has a Forward P/S ratio of 0.00. This means the market is valuing TCRT at $0.00 for every dollar of expected revenue over the next 12 months.

TCRT Valuation